Compare CVRX & QTRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CVRX | QTRX |
|---|---|---|
| Founded | 2000 | 2007 |
| Country | United States | United States |
| Employees | 223 | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Biotechnology: Laboratory Analytical Instruments |
| Sector | Health Care | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 139.3M | 160.0M |
| IPO Year | 2021 | 2017 |
| Metric | CVRX | QTRX |
|---|---|---|
| Price | $5.86 | $4.32 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 4 | 2 |
| Target Price | ★ $10.50 | $6.00 |
| AVG Volume (30 Days) | 268.9K | ★ 1.2M |
| Earning Date | 05-11-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 23.02 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $56,651,000.00 | $37,632,000.00 |
| Revenue This Year | $17.17 | $25.49 |
| Revenue Next Year | $17.69 | $10.04 |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | 10.45 | ★ 64.52 |
| 52 Week Low | $4.37 | $2.40 |
| 52 Week High | $11.30 | $8.77 |
| Indicator | CVRX | QTRX |
|---|---|---|
| Relative Strength Index (RSI) | 53.12 | 67.91 |
| Support Level | $5.06 | $2.98 |
| Resistance Level | $5.95 | $6.27 |
| Average True Range (ATR) | 0.33 | 0.34 |
| MACD | 0.12 | 0.10 |
| Stochastic Oscillator | 100.00 | 98.91 |
CVRx Inc is a commercial-stage medical device company focused on developing, manufacturing, and commercializing minimally invasive neuromodulation solutions for patients with cardiovascular diseases. Its proprietary platform technology, Barostim, is designed to leverage the power of the brain to address the imbalance of the Autonomic Nervous System, which causes heart failure and other cardiovascular diseases. Barostim provides Baroreflex Activation Therapy which in turn triggers an autonomic response to the heart. The majority of revenue is derived from the USA market.
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.